Physician profile
Thein Swe
NPI 1124435003
$8,711.99
in general payments reported to CMS, 2019-2025
15 companies · $3,389 in 2025
The $3,389 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,288 · 2021: $929 · 2023: $639 · 2024: $2,467 · 2025: $3,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,383 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,382.90 |
| Education | $112.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,970.51 | 2020-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,821.41 | 2020-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $1,056.49 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $928.59 | 2020-2025 | |
| Glaxosmithkline, LLC. | $850.46 | 2020-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $612.84 | 2020-2025 | Orencia |
| Ucb, INC. | $503.96 | 2024-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $364.17 | 2024-2025 | |
| Lilly USA, LLC | $185.91 | 2024-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.76 | 2020-2025 | Ofev, Jascayd |
| Horizon Therapeutics Plc | $139.58 | 2020 | |
| Genentech USA, INC. | $79.41 | 2020-2025 | Actemra, Gazyva |
| Aurinia Pharma U.S., INC. | $25.90 | 2025 | Lupkynis |
| Sandoz INC. | $19.83 | 2024 | Hyrimoz |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thein Swe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.